Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2025)
Mesoblast's (MESO) quarterly Total Non-Current Liabilities came in at $79.6 million in Q4 2025, down 33.32% year-on-year from $119.3 million in Q4 2024, and down 5.98% quarter-over-quarter from $84.6 million in Q2 2025.
Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends
Mesoblast has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $79.6 million for Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $79.6 million, down 33.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $79.6 million (down 33.32% YoY), and the FY2025 annual result was $84.6 million, down 26.78% from the prior year.
- Total Non-Current Liabilities came in at $79.6 million for Q4 2025 at Mesoblast, down from $84.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $130.2 million in Q4 2023 to a low of $66.6 million in Q1 2021.
- The 5-year median for Total Non-Current Liabilities is $112.9 million (2022), against an average of $102.5 million.
- Across the five-year window, Total Non-Current Liabilities sank 34.2% in 2021 and surged 68.61% in 2022, its largest moves.
- Mesoblast's Total Non-Current Liabilities stood at $111.0 million in 2021, then advanced by 2.26% to $113.5 million in 2022, then increased by 14.72% to $130.2 million in 2023, then slipped by 8.36% to $119.3 million in 2024, then slumped by 33.32% to $79.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $79.6 million (Q4 2025), $84.6 million (Q2 2025), and $119.3 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | 79.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79.55 Mn |
| Jun 30, 2025 | 84.62 Mn |
| Dec 31, 2024 | 119.31 Mn |
| Jun 30, 2024 | 115.56 Mn |
| Dec 31, 2023 | 130.19 Mn |
| Jun 30, 2023 | 125.60 Mn |
| Mar 31, 2023 | 114.36 Mn |
| Dec 31, 2022 | 113.48 Mn |
| Sep 30, 2022 | 112.89 Mn |
| Jun 30, 2022 | 113.73 Mn |
| Mar 31, 2022 | 112.38 Mn |
| Dec 31, 2021 | 110.98 Mn |
| Sep 30, 2021 | 69.17 Mn |
| Jun 30, 2021 | 69.05 Mn |
| Mar 31, 2021 | 66.65 Mn |
| Dec 31, 2020 | 77.54 Mn |
| Sep 30, 2020 | 86.37 Mn |
| Jun 30, 2020 | 94.13 Mn |
| Mar 31, 2020 | 101.29 Mn |
| Dec 31, 2019 | 112.48 Mn |